Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicorandil peri-PCI to reduce inflammatory response in acute anterior STEMI
ChiCTR2400080253Phase 4Recruiting
- Sponsor
- Xuzhou Central Hospital
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in myocardial infarction (MI) comparing Experimental nicorandil arm with Placebo control arm (2 arms). Primary endpoint: Cytokines (IL-1β, IL-2, IL-5, IL-6, IL-8, IL-12p70, IL-17, TNF-α, IFN-γ, IFN-α, IL-4, IL-10). Started Jan 2024; status: recruiting.
02
Drugs
nicorandil
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2400080253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080253.